ProCE Banner Activity

Phase II Study of Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine in Early-Stage Classical Hodgkin Lymphoma

Conference Coverage

The combination of brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine achieved high response rates in patients with early-stage classical Hodgkin lymphoma without bulky disease.

Released: December 13, 2023


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AbbVie Inc., AstraZeneca, Daiichi Sankyo, Inc., Merck Sharp & Dohme LLC, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc, and Seagen Inc.

AbbVie Inc.


Daiichi Sankyo, Inc.

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation

Regeneron Pharmaceuticals, Inc

Seagen Inc.